Investigational drug · Phase 2
QHRD106
Also called: Middle
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Ischemic Stroke.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "QHRD106"
First trial start
2026
Jan 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QHRD106", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Ischemic Stroke
Approved drugs for the same conditions: Stroke prevention · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "QHRD106" as an intervention, largest first.
- Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.Pivotal-lookingRecruiting
Changzhou Qianhong Bio-pharma Co., Ltd.Industry
NCT07396337 · 320 participants (planned) · Start Jan 19, 2026 · Primary completion Oct 31, 2026
Drug: QHRD106 Injection (Low-dose group); QHRD106 Injection (Middle-dose group) and 2 more · For: Acute Ischemic Stroke
Sites: Nanjing, China
Changzhou Qianhong Bio-pharma Co., Ltd.Industry
NCT06388772 · 74 participants · Start Jul 5, 2021 · Primary completion Jul 22, 2022
Drug: QHRD106 Injection; placebo · For: Acute Ischemic Stroke
Sites: Nanjing, China
Changzhou Qianhong Bio-pharma Co., Ltd.Industry
NCT06380699 · 56 participants · Start Mar 16, 2023 · Primary completion Nov 16, 2023
Drug: QHRD106 Injection; Human Urinary Kallidinogenase and 1 more · For: Acute Ischemic Stroke
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- Animal protein supply, cognitive ageing and female-male dementia disparities: a global ecological analysis.
You W, Sumar B, Endrawes G, et al. · Future Sci OA 2027
- Mortality and disability after hospitalisation for injuries in low-income and middle-income countries: a cohort study.
· Lancet Glob Health 2027
- Interventions to reduce paediatric cancer treatment abandonment in low-income and middle-income countries: a systematic review and meta-analysis.
Gillipelli SR, Schaeffer AR, McAtee CL, et al. · Lancet Glob Health 2027
- Physical activity, sedentary behaviour, and healthy ageing in older adults.
Koemel NA, Valenzuela PL, D'Amore C, et al. · Lancet Healthy Longev 2027
- Promoting physical activity for healthy ageing in low-income and middle-income countries: a public health priority.
Chhetri JK, Chan P · Lancet Healthy Longev 2027
- 2022 WHO estimates for overall and human papillomavirus test-based cervical cancer screening coverage worldwide: a review and synthetic analysis.
Serrano B, Roura E, Alemany L, et al. · Lancet Glob Health 2027
Also in development for Acute Ischemic Stroke
- TAK-755rADAMTS13, recombinant ADAMTS13Phase 33 trials
Takeda · Thrombotic Thrombocytopenic Purpura (TTP), Acute Ischemic Stroke
- SovateltideIRL-1620, PMZ-1620Phase 32 trials
Pharmazz, Inc. · Traumatic Brain Injury, Acute Ischemic Stroke, Cerebral Stroke
- JX10Phase 31 trial
Corxel Pharmaceuticals · Acute Ischemic Stroke
- SHPL-49Phase 31 trial
Shanghai Hutchison Pharmaceuticals Limited · Acute Ischemic Stroke
- LT3001Phase 23 trials
Lumosa Therapeutics Co., Ltd. · Acute Ischemic Stroke
- LT3001 DrugPhase 22 trials
Shanghai Pharmaceuticals Holding Co., Ltd · Acute Ischemic Stroke
- B2065Phase 21 trial
Tasly Pharmaceutical Group Co., Ltd · Acute Ischemic Stroke
- BB-031DTRI-031Phase 21 trial
Basking Biosciences, Inc. · Acute Ischemic Stroke
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.